Huawei plans more AI pharma partnerships, mainly with Chinese drugmakers

Huawei will expand AI collaborations with pharmaceutical firms, focusing on Chinese drugmakers, according to William Zhang, president of its healthcare unit. The company markets compound-screening tools that run on its Ascend and Kunpeng chips, part of a domestic hardware stack developed after U.S. export restrictions.